IDEAYA Biosciences · 12 hours ago
Senior Director, Health Economics and Outcomes Research / Real World Evidence
South San Francisco, CA
Full-time
Onsite
Director/Executive
$282K/yr - $349K/yr
10+ years expIDEAYA Biosciences is a precision medicine oncology company focused on discovering and developing transformative therapies for cancer. The Senior Director of Health Economics and Outcomes Research / Real World Evidence will shape and execute the HEOR/RWE strategy for the launch of darovasertib in metastatic uveal melanoma and will collaborate with various teams to generate robust evidence and support reimbursement decisions.
BiotechnologyHealth CareOncologyTherapeutics
Responsibilities
Develop and execute the HEOR and RWE strategy to support US value demonstration for darovasertib at launch and through its lifecycle
Collaborate with Market Access, Medical Affairs and Clinical Development to evaluate data gaps and develop robust evidence generation and publication plans
Develop and execute core evidence-generation activities including chart reviews, literature reviews, PRO studies, and micro-costing analyses to strengthen the clinical and economic differentiation of the product
Design and implement real-world data analyses to articulate the current patient demographics, treatment patterns, and outcomes for mUM patients
Develop comprehensive health economic model analyses to demonstrate value, inform pricing strategy, and support reimbursement decisions
Partner with Market Access to develop robust and compelling clinical, humanistic, and economic value propositions and oversee development of AMCP and Global Value Dossiers
Lead the external dissemination of HEOR/RWE deliverables including publications, presentations, and professional conferences
Develop, train, and implement the resources that support field HEOR efforts with key customers; ensure programs and materials comply with SOPs and Medical, Legal & Regulatory (MLR) reviews
Engage and collaborate with external partners including payers, providers, and other access decision-makers to establish / maintain strong partnerships and gather insights
Support field team engagements during Preapproval Information Exchange (PIE) and post-approval interactions to educate payers and provider access stakeholders on darovasertib
Stay current with advancements in methodologies and best practices; Closely monitor new trends in health policy and payer environment and integrate into cross-functional strategies
Influence the design of IDEAYA’s clinical development programs through global price and market access and commercial opportunity assessments
Oversee budgeting and financial planning for all HEOR/RWE activities
Qualification
Required
Advanced, doctoral level degree in related discipline with at least 10-15 years of related experience
Experience in Biotech/Pharmaceutical industry in US HEOR/RWE and with market access strategies
Demonstrated success with US commercialization and launches
Deep technical knowledge and experience with Clinical and HEOR / RWE data sets, methodologies, analyses, and processes to optimize execution of value evidence tactics
Experience developing US and global value evidence generation plans for pipeline assets
Experience establishing relationships with clinical and HEOR experts
Experience interacting with US access decision-makers
Excellent communication and presentation skills, ability to present to diverse stakeholders including external partners, healthcare professionals and senior leaders
Excellent organizational, project management and problem-solving skills
Ability to thrive in a fast-evolving environment
In-office role (4x per week) with 15% estimated travel to vendor partners and relevant conferences/meetings as deemed necessary
Preferred
Experience with rare disease and oral drugs is strongly preferred
Benefits
Medical/dental/vision coverage (100% company paid for employees and 90% company paid for dependents)
401k
ESPP
Wellness programs
Company
IDEAYA Biosciences
IDEAYA Biosciences is an oncology-focused biotechnology company that develops therapeutics for patients with genetically-defined cancers.
51-200 employees
Funding
Current Stage
Public CompanyTotal Funding
$694.1MKey Investors
5AM Ventures
2024-07-09Post Ipo Equity· $263M
2023-10-24Post Ipo Equity· $125M
2022-09-14Post Ipo Equity· $80M
Leadership Team
Yujiro S. Hata
CEO
Paul A. Stone
Chief Financial Officer & General Counsel
Recent News
2025-12-16
Company data provided by crunchbase